Terminal / Weight Loss

Survodutide

Phase 3

aka BI 456906

Dual GLP-1/glucagon agonist in phase 3 for obesity and fatty liver.

Mechanism

Activates GLP-1 and glucagon receptors: appetite down, energy expenditure up. The glucagon arm is also why it's being pushed hard for MASH, the serious fatty-liver disease.

Regulatory & Safety Status

Investigational (Boehringer Ingelheim and Zealand Pharma). Not approved.

Research

2026Hepatology (Baltimore, Md.)

Weight reduction-dependent/-independent effects of survodutide on liver endpoints: Mediation analysis of a phase 2 trial in MASH

2026Journal of the American Heart Association

Cardiovascular Effects of Glucagon Receptor Signaling Alone and Combined With Glucagon-Like Peptide-1 Receptor Signaling in Multiagonists: A Narrative Review With a Translational Focus

2026Cureus

Efficacy and Safety of Dual and Triple Glucagon-Like Peptide-1-Based Polyagonists in Metabolic Dysfunction-Associated Steatotic Liver Disease and Steatohepatitis: A Systematic Review and Meta-Analysis

2026Diabetes, obesity & metabolism

Dual Glucagon and GLP-1 Receptor Agonist Survodutide Improves Biomarkers of Beta-Cell Function and Insulin Sensitivity in People With Type 2 Diabetes or Living With Overweight/Obesity

2024PubMed

Latest survodutide research

Related Compounds

Weight Loss

Retatrutide

Phase 3

Triple agonist (GLP-1, GIP, glucagon) in phase 3 for obesity. The one everyone's watching.

Weight Loss

Tirzepatide

Approved

Approved dual agonist (GLP-1 and GIP). Currently the strongest thing you can get with a prescription.